<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(7)</volume><submitter>Eggers KM</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Current guidelines stress the importance of early invasive assessment of patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), in particular those at high risk. However, supporting scientific evidence is limited.&lt;h4>Aims&lt;/h4>We aimed to investigate the prognostic impact of the timing of coronary angiography in a large cohort of NSTE-ACS patients.&lt;h4>Methods&lt;/h4>We performed a retrospective analysis including 34,666 NSTE-ACS patients registered from 2013 to 2018 in the SWEDEHEART registry. The prognostic implications of the timing of coronary angiography on a continuous scale and within &lt;24 vs 24-72 hours were assessed using Cox regression analyses.&lt;h4>Results&lt;/h4>The median time interval from admission to invasive assessment was 32.8 (25th, 75th percentiles 20.4-63.8) hours. There was no apparent time window within 96 hours from admission that provided prognostic benefit. Coronary angiography within 24-72 hours (vs &lt;24 hours) was not associated with worse outcome overall (all-cause mortality: hazard ratio 1.01, 95% confidence interval [CI] 0.92-1.11; major adverse events: hazard ratio 1.04, 95% CI: 0.98-1.12). Interaction analyses indicated a greater relative benefit of coronary angiography &lt;24 hours in some lower-risk groups (women, non-diabetics, patients with minor troponin elevation) but neutral effects in higher-risk groups (defined by age or the GRACE 2.0 score).&lt;h4>Conclusions&lt;/h4>These Swedish data do not provide support for an early invasive strategy in NSTE-ACS, especially in high-risk patients. Our results suggest that the timing of invasive assessment should rather be based on individualised decisions integrating symptoms and risk panorama than on strictly defined time intervals.</pubmed_abstract><journal>EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology</journal><pagination>582-589</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10241271</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from the nationwide SWEDEHEART registry.</pubmed_title><pmcid>PMC10241271</pmcid><pubmed_authors>Eggers KM</pubmed_authors><pubmed_authors>Lindahl B</pubmed_authors><pubmed_authors>James SK</pubmed_authors><pubmed_authors>Jernberg T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from the nationwide SWEDEHEART registry.</name><description>&lt;h4>Background&lt;/h4>Current guidelines stress the importance of early invasive assessment of patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), in particular those at high risk. However, supporting scientific evidence is limited.&lt;h4>Aims&lt;/h4>We aimed to investigate the prognostic impact of the timing of coronary angiography in a large cohort of NSTE-ACS patients.&lt;h4>Methods&lt;/h4>We performed a retrospective analysis including 34,666 NSTE-ACS patients registered from 2013 to 2018 in the SWEDEHEART registry. The prognostic implications of the timing of coronary angiography on a continuous scale and within &lt;24 vs 24-72 hours were assessed using Cox regression analyses.&lt;h4>Results&lt;/h4>The median time interval from admission to invasive assessment was 32.8 (25th, 75th percentiles 20.4-63.8) hours. There was no apparent time window within 96 hours from admission that provided prognostic benefit. Coronary angiography within 24-72 hours (vs &lt;24 hours) was not associated with worse outcome overall (all-cause mortality: hazard ratio 1.01, 95% confidence interval [CI] 0.92-1.11; major adverse events: hazard ratio 1.04, 95% CI: 0.98-1.12). Interaction analyses indicated a greater relative benefit of coronary angiography &lt;24 hours in some lower-risk groups (women, non-diabetics, patients with minor troponin elevation) but neutral effects in higher-risk groups (defined by age or the GRACE 2.0 score).&lt;h4>Conclusions&lt;/h4>These Swedish data do not provide support for an early invasive strategy in NSTE-ACS, especially in high-risk patients. Our results suggest that the timing of invasive assessment should rather be based on individualised decisions integrating symptoms and risk panorama than on strictly defined time intervals.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2026-05-13T14:33:09.803Z</modification><creation>2025-04-07T10:18:29.103Z</creation></dates><accession>S-EPMC10241271</accession><cross_references><pubmed>35352681</pubmed><doi>10.4244/EIJ-D-21-00982</doi><doi>10.4244/eij-d-21-00982</doi></cross_references></HashMap>